Biomarkers linked potential ICPI efficacy were higher in MTAP‐intact NSCLC including higher TMB (9.4 vs. 8.6, p = 0.001) and low (30% vs. 28%, p = 0.01) and high (32% vs. 30%, p = 0.01) PD‐L1 IHC staining. Here, MTAP is linked to non-small cell lung carcinoma.